<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961257</url>
  </required_header>
  <id_info>
    <org_study_id>CABASTY</org_study_id>
    <nct_id>NCT02961257</nct_id>
  </id_info>
  <brief_title>Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel</brief_title>
  <acronym>CABASTY</acronym>
  <official_title>Randomized Multicenter, Phase III Trial Evaluating the Safety of 2 Schedules of Cabazitaxel (Bi-weekly Versus Tri-weekly) Plus Prednisone in Elderly Men (≥ 70 Years) With mCRPC Previously Treated With a Docetaxel-containing Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the incidence of grade ≥ 3 neutropenia and/or
      neutropenic complications (febrile neutropenia, neutropenic infection) with two schedules of
      cabazitaxel (bi-weekly versus tri-weekly) plus prednisone in elderly men (≥ 70 years) with
      mCRPC previously treated with a docetaxel-containing regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, open-label, phase 3 trial in mCRPC patients aged ≥ 70 years.

      Treatment:

        -  Arm A : cabazitaxel 25 mg/m² on Day 1 of a 3-week cycle plus daily prednisone or

        -  Arm B: cabazitaxel 16 mg/m² on Day 1 and Day 15 of a 4-week cycle plus daily prednisone.

        -  Treatment will be continued for a maximum of 10 cycles unless there is documented
           disease progression or unacceptable toxicity.

        -  Standard cabazitaxel premedication will be used

        -  Prophylactic G-CSF (GRANOCYTE) will be injected from Day 3 to Day 7 after every cycle of
           cabazitaxel if neutrophil count is&gt; 2000/mm3, only 3 days).

        -  All new hormonal treatment, including ODM-201, prior to study entry is allowed.

        -  Patients who received Radium-223 are eligible for this study

        -  Treatment with LHRH should not be discontinued.

      Exploratory assessments:

      CT-Scan (abdominal/pelvic/chest) or whole body MRI and Bone scan: at screening, every 3
      months and EOT.

      FACT-P questionnaire:at C1D1,each subsequent visit and EOT

      Number of subjects:

      Total:170 (85 per arm)

      Statistical analysis:

      A sample size of 77 evaluable patients per arm will achieve 80% power to detect a 20%
      difference in G3 neutropenia incidence between the 2 arms. The incidence in group cabazitaxel
      25 mg/m2 q3w is assumed to be 32% and 12% on bi-weekly cabazitaxel arm. The test used is a
      two-sided Fisher's exact test at 0.05 significance level. Assuming 10% non-evaluable
      patients, 85 patients should be included in each arm for a total of 170. Patients will be
      stratified according to G8 score and previous ARtargeted agent (abiraterone or enzalutamide)
      before randomization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of grade ≥ 3 neutropenia and/or neutropenic complications</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>To evaluate the incidence of grade ≥ 3 neutropenia (measured at Day 7 and Day 14) and/or neutropenic complications (febrile neutropenia, neutropenic infection) with two schedules of cabazitaxel (bi-weekly versus tri-weekly) plus prednisone in elderly men (≥ 70 years) with mCRPC previously treated with a docetaxel-containing regimen.
with two schedules of -+cabazitaxel (bi-weekly versus tri-weekly) plus prednisone in elderly men with mCRPC previously treated with a docetaxel-containing regimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose reductions</measure>
    <time_frame>through study completion, an average of 40 weeks</time_frame>
    <description>Up to 11 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological progression-free survival (rPFS)</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>CT-Scan (abdominal/pelvic/chest) or whole body MRI and Bone scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA progression</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Assessed at C1D1, at every each subsequent visit and EOT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first symptomatic Skeletal-Related Event (SRE) and incidence of SREs</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Assessed at C1D1, at every each subsequent visit and EOT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to opioid treatment (if relevant)</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific antigen (PSA) response rate</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Assessed at C1D1, at every each subsequent visit and EOT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (FACT-P)</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Assessed at C1D1, at every each subsequent visit and EOT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) in measurable lesions (RECIST criteria 1.1 - only on metastasis</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>CT-Scan (abdominal/pelvic/chest) or whole body MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors influencing survival</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Factors influencing survival (duration of response to first ADT, serum testosterone, cumulative dose of cabazitaxel, neutrophils/lymphocytes ratio, Gleason score, G8, grade ≥3 neutropenia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of grade ≥3 neutropenia</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Hematology every week until EOT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade ≥3 neutropenia duration ( from date of onset of grade ≥ 3 until grade ≤ 2)</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Hematology every week until EOT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of grade ≥3 neutropenia by cycle</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Analysis of grade ≥3 neutropenia and/or neutropenia by cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose delay</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Prostate Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabazitaxel 25 mg/m² intravenously over 1 hour on Day 1of a 3-week cycle, plus prednisone (or prednisolone) 10 mg orally given daily for a maximum of 10 cycles (ie 30 weeks of treatment).
Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every cycle of cabazitaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabazitaxel 16 mg/m2 on Day 1 and Day 15 of a 4-week cycle plus prednisone (or prednisolone) 10 mg per day up to 10 cycles (ie 40 weeks of treatment). Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every cycle of cabazitaxel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cabazitaxel</intervention_name>
    <description>Arm A : cabazitaxel 25 mg/m² on Day 1 of a 3-week cycle plus daily prednisone or
Arm B: cabazitaxel 16 mg/m² on Day 1 and Day 15 of a 4-week cycle plus daily prednisone.
Treatment will be continued for a maximum of 10 cycles unless there is documented disease progression or unacceptable toxicity.
Standard cabazitaxel premedication will be used</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Jevtana</other_name>
    <other_name>XRP6258</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Arm A:plus prednisone 10 mg orally given daily for a maximum of 10 cycles Arm B: plus prednisone 10 mg orally given per day up to 10 cycles</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte colony-stimulating factor (G-CSF)</intervention_name>
    <description>Primary prophylaxis with Granulocyte Colony-Stimulating Factor (G-CSF) will be injected from Day 3 to Day 7 after every cycle of cabazitaxel (if neutrophil count is &gt;2000/mm3, only 3 days)</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Granocyte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient aged ≥ 70 years with mCRPC previously treated with docetaxel Sponsor Protocol:
             CABASTY Date 6thJune 2016 Version 4.0 - Confidential Page 6 of 58

          2. Medical or surgical castration with castrate level of testosterone (&lt; 50 ng/dl)

          3. Progressive disease according to physician judgement

          4. Histologically proven prostate carcinoma

          5. Health status allowing use of chemotherapy: G8 &gt; 14; or G8 score ≤ 14 with geriatric
             assessment concluding to reversible impairment allowing use of chemotherapy

          6. ECOG-PS 0, 1 or 2(ECOG-PS 2 should be related to prostate cancer)

          7. Adequate hematologic, liver and renal functions:

               1. Neutrophil count ≥1.5 109/L

               2. Haemoglobin ≥10 g/ dL

               3. Platelet count ≥100.109/L

               4. Total bilirubin ≤ 1 the upper limit of normal (ULN)

               5. Transaminases ≤ 1.5 ULN

               6. Serum creatinine ≤ 2.0 ULN

          8. Ongoing LHRH therapy at study entry

          9. Signed informed consent

        Exclusion Criteria:

          1. History of severe hypersensitivity reaction (≥grade 3) to docetaxel

          2. History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing
             drugs

          3. Uncontrolled severe illness or medical condition (including uncontrolled diabetes
             mellitus)

          4. Concurrent or planned treatment with strong inhibitors or strong inducers of
             cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are
             already on these treatments) (see Appendix E)

          5. PS &gt;2 not related to prostate cancer disease

          6. G8 ≤ 14 with geriatric assessment contra-indicating standard cabazitaxel regimen

          7. Concomitant vaccination with yellow fever vaccine

          8. Patient who cannot be regularly followed or cannot answer to quality of life
             questionnaires because of psychological, social, familial or geographic reasons

          9. Participation in another clinical trial with any investigational drug within 30 days
             prior to study enrolment.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephane OUDARD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Européen Georges Pompidou, Oncology Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Réza ELAIDI, PhD</last_name>
    <phone>00 33 (1)56 09 23 40</phone>
    <email>reza-thierry.elaidi-ext@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elena BRAYCHENKO, MD</last_name>
    <phone>00 33 (1)56 09 34 34</phone>
    <email>elena.braychenko-ext@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine THIERY-VUILLEMIN, MD</last_name>
      <email>a.thieryvuillemin@mac.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint André, CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amandine QUIVY, MD</last_name>
      <email>amandine.quivy@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Maurice Tubiana</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Polyclinique Saint-Côme</name>
      <address>
        <city>Compiègne</city>
        <zip>60204</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kais ALDABBAGH, MD</last_name>
      <email>Kais.aldabbagh@stcome.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Henri-Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>carolina.saldana@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Carolina SALDANA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>T-Ryckewaert@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas RYCKEWAERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Belle-Isle</name>
      <address>
        <city>Metz</city>
        <zip>57045</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérôme PLAZA, MD</last_name>
      <email>jerome.plaza@hp-metz.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie du Gard - CHU</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>nadine.HOUEDE@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Nadine HOUEDE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mostefa BENNAMOUN, MD</last_name>
      <email>Mostefa.Bennamoun@imm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane OUDARD, MD</last_name>
      <phone>00 33 (1) 56 09 34 76</phone>
      <email>stephane.oudard@egp.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ahmed KHALIL, MD</last_name>
      <email>ahmed.khalil@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme ALEXANDRE, MD</last_name>
      <email>jerome.alexandre@cch.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Marc TOURANI, MD</last_name>
      <email>Jean-Marc.TOURANI@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric DI FIORE, MD</last_name>
      <email>Frederic.DiFiore@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine de Radiologie</name>
      <address>
        <city>Saint-brieuc</city>
        <zip>22015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Claire HARDY-BESSARD, MD</last_name>
      <email>ac.hardy@cario-sante.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HIA Bégin 69 avenue de Paris</name>
      <address>
        <city>Saint-Mandé</city>
        <zip>94160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole HELISSEY, MD</last_name>
      <email>carole.helissey@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Sens</name>
      <address>
        <city>Sens</city>
        <zip>89100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laure CHAUVENET, MD</last_name>
      <email>LCHAUVENET@ch-sens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>philippe.barthelemy@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe BARTHELEMY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital FOCH</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2016</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

